Combination of Imipenem-Cilastatin-Relebactam and Amoxicillin in the Antibiotic Regimen in Two Cases of Mycobacterium abscessus Lung Infection

is a difficult-to-treat, multidrug-resistant human pathogen. Relebactam has been shown to inhibit β-lactamase (BLA ) and increase the activity of imipenem and amoxicillin. We present two cases of lung infection due to , one caused by subsp and the other by subsp . Both strains showed moderate sensit...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2024-07, Vol.16 (7), p.e65112
Main Authors: Vogiatzoglou, Anastasios I, Hadji Μitrova, Maria, Papadaki, Eleni, Sionidou, Maria, Nikopoulou, Anna, Kontos, Fanοurios, Papaventsis, Dimitrios, Papavasileiou, Apostolos, Manika, Katerina
Format: Article
Language:English
Subjects:
Antibiotics
Drug dosages
Hemoptysis
Infections
Infectious Disease
Lung diseases
Medical imaging
Pathogens
Patients
Penicillin
Pulmonology
Tuberculosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:is a difficult-to-treat, multidrug-resistant human pathogen. Relebactam has been shown to inhibit β-lactamase (BLA ) and increase the activity of imipenem and amoxicillin. We present two cases of lung infection due to , one caused by subsp and the other by subsp . Both strains showed moderate sensitivity to imipenem, and the second strain was also resistant to macrolides. A multidrug antibiotic regimen was administered in both cases, which included imipenem/cilastatin/relebactam adjusted to the estimated glomerular filtration rate (eGFR) and amoxicillin for three months. The regimen was well tolerated and both patients improved both clinically and radiologically after the first phase of treatment. The results of our patients indicate that the combination of imipenem/cilastatin/relebactam and amoxicillin could be used in the future in difficult infections by .
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.65112